Cellectar Biosciences, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The company is a clinical-stage biopharmaceutical developer focused on cancer therapies using its phospholipid drug conjugate (PDC) platform. This is an annual report, not a report for 2019 Q4 alone.
Financial results and liquidity
| Metric | 2019 | 2018 | Change / context |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | Operations remain dependent on external financing. |
| Research and development expense | $9.0 million | $6.8 million | Up $2.2 million, or 32%, primarily from clinical activity, patient enrollment and manufacturing. |
| General and administrative expense | $5.2 million | $4.8 million | Up $0.4 million, or 8%. |
| Operating loss | $14.2 million | $13.3 million | Loss widened; 2018 included a $1.7 million goodwill impairment. |
| Net loss | $14.1 million | $13.2 million | 2018 net loss attributable to common stockholders was $15.5 million after a $2.2 million preferred-stock deemed dividend; 2019 had no such dividend. |
| Basic and diluted loss per share | $1.84 | $5.23 | Per-share comparison was affected by the higher weighted-average share count in 2019 and the 2018 deemed dividend. |
| Cash used in operations | $11.7 million | $11.4 million | Reflects continued operating cash burn. |
| Cash, cash equivalents and restricted cash | $10.6 million | $13.3 million | Down $2.7 million; no cash was restricted at year-end 2019. |
Year-end 2019 current assets were $11.4 million and current liabilities were $2.8 million, yielding reported working capital of approximately $8.6 million. Total liabilities were $3.2 million, including $528,000 of lease liabilities; the filing reports no conventional funded debt balance. No meaningful operating margin is available because the company had no product revenue.
Financing provided $9.0 million net in 2019, primarily from a May stock-and-warrant offering. The offering issued 4.0 million common shares and warrants for a further 4.0 million shares at $2.40 per share. At year-end, 9.27 million warrants were outstanding across multiple offerings. Common shares outstanding increased from 4.73 million at December 31, 2018 to 9.39 million at December 31, 2019.
Business progress and material changes
- CLR 131, the lead iodine-131 radiotherapeutic PDC, was being studied in a Phase 2 trial in relapsed/refractory hematologic cancers and Phase 1 studies in multiple myeloma and pediatric cancers. A Phase 1 head-and-neck cancer study with external-beam radiation began enrollment in Q4 2019.
- R&D spending shifted toward clinical development: clinical project costs rose from $1.2 million to $3.6 million, and manufacturing-related costs rose from $1.4 million to $2.8 million. Preclinical project costs fell from $1.9 million to $0.3 million as some studies concluded.
- The Pierre Fabre collaboration expired in January 2019; Cellectar said it continued to assess eligible program molecules. Other partnered programs included collaborations with Avicenna, Onconova and Orano Med.
- The Madison radiopharmaceutical manufacturing facility had been shut down, with CPDC serving as the exclusive supplier of CLR 131 drug product for ongoing research and clinical studies.
Outlook, commentary and key risks
- Management estimated that year-end cash would fund budgeted operations into the first quarter of 2021. This is not a guarantee: continued operations beyond that point depend on additional financing, a strategic transaction or other funding, and the auditor reported substantial doubt about the company’s ability to continue as a going concern.
- The company expects continuing operating losses and negative operating cash flows and has no approved commercial products. Future clinical, regulatory, manufacturing and commercialization costs may require additional capital, potentially dilutive equity or debt financing, or partnering that could surrender economic or intellectual-property rights.
- After year-end, in February 2020, Cellectar announced positive CLOVER-1 Phase 2 results. For multiple myeloma, it reported a 42.8% overall response rate at the highest dose and a 34.5% combined response rate in the approximately 50 mCi and highest-dose groups (n=33); it also reported clinical benefit in all 43 evaluable patients. These are company-reported clinical findings, not 2019 financial results, and require confirmation in further study.
- Key risks include clinical efficacy and safety uncertainty, regulatory delays, reliance on one CLR 131 supplier and outsourced research, access to capital, competition, potential dilution, and the possibility that clinical results will not support approval or market adoption. The filing also identifies cybersecurity, reimbursement and early-2020 public-health disruption risks.
- The company reported effective disclosure controls and internal control over financial reporting at December 31, 2019. Its auditor did not provide an internal-controls attestation.
Important facts for investors to verify
- Whether financing or other strategic arrangements extend the stated cash runway, and the resulting dilution, debt terms or rights granted to partners.
- Cash burn and clinical/manufacturing spending relative to management’s first-quarter 2021 runway estimate.
- Full CLOVER-1 trial data, patient counts and response durability, safety findings, dose regimen and the design and progress of follow-up studies.
- CPDC’s ability to supply clinical and potential commercial quantities of CLR 131, and whether a qualified alternate supplier is available.
- Potential dilution from outstanding warrants, options and convertible preferred shares; warrant exercises are not assured.
- Regulatory progress, including the status and requirements for CLR 131’s various indications and the conditions attached to orphan, fast-track and rare-pediatric designations.